- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06099639
Medical Access Program for Patritumab Deruxtecan
Medical Access Program for Patritumab Deruxtecan (HER3 DXd, U3-1402)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Medical Access Program which will be available to adult patients in the US with metastatic or locally advanced EGFRm NSCLC who have received at least 2 prior systemic therapies, who have no alternative commercially available treatment options, and are not able to enter a clinical trial.
In this Medical Access Program, eligible patients will be treated with HER3-DXd and will continue to receive treatment until any of the following occurs:
- Disease progression
- Unacceptable toxicity
- The benefit-risk no longer favors the individual
- HER3-DXd becomes commercially available in the US and reimbursement is approved for the concerned indication of the Medical Access Program.
- Withdrawal of consent
- Pregnancy
- Physician discretion
- Death
Study Type
Expanded Access Type
- Treatment IND/Protocol
Contacts and Locations
Study Contact
- Name: Contact for Program Information
- Phone Number: 9089926400
- Email: patient.access@bionicalemas.com
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Available
- Roswell Park Comprehensive Cancer Center
-
Contact:
- Principal Investigator
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Available
- Providence Portland Medical Center
-
Contact:
- Principal Investigator
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria - Initial Requests
- Written informed consent
- Male or female aged ≥18 years (or local regulatory requirements)
- Histologically or cytologically documented locally advanced or metastatic EGFRm NSCLC not amenable to curative surgery or radiation
Documentation of radiological disease progression whilst on/after receiving most recent treatment regimen for locally advanced or metastatic disease. Patients must have received both of the following:
- Prior treatment with any EGFR TKI, with at least one of them being osimertinib. Patients receiving an EGFR TKI at the time of signing informed consent should continue to take the EGFR TKI until 5 days prior to the first infusion of HER3 DXd.
- Systemic therapy with at least 1 PBC regimen.
- Documentation of an EGFR-activating mutation detected from tumor tissue or blood (exon 19 deletion or L858R mutation).
- Eastern Cooperative Oncology Group performance status of 0 or 1 at the time of entering the Medical Access Program.
- Adequate levels of bone marrow reserve and organ function
- 7. Female patients of childbearing potential must have a negative urine or serum pregnancy test at the time of entering the Medical Access Program and must be willing to use highly effective contraception during the treatment period and for at least 7 months following the last dose of HER3-DXd. Additionally, female patients must agree to not donate, or retrieve for their own use, eggs from the time of entering the Medical Access Program and throughout the treatment period, and for at least 7 months after the final HER3-DXd administration. Male patients with female partners who are able to become pregnant must be willing to use a highly effective form of contraception or avoid intercourse during the treatment period and for at least 4 months following the last dose of HER3- DXd. Additionally, male patients must agree not freeze or donate sperm from time of entering the Medical Access Program and throughout the treatment period, and for at least 4 months after final dose of HER3- DXd.
- Life expectancy of >3 months
Inclusion Criteria - Resupply Requests
- Treating physician must confirm that the patient is deriving continued benefit from treatment.
- Treating physician must confirm that all required safety information has been reported as per local laws/regulations,
Exclusion Criteria - Initial Requests
- Patient has participated in the HERTHENA-Lung02 'Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer' (NCT05338970) clinical trial.
- Patient has previous or current histologic or cytologic evidence of small cell OR combined small cell/non-small cell disease in the archival tumor tissue or pre treatment tumor biopsy.
- Patient has any history of ILD (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging at the time of entering the Medical Access Program.
- Patient has clinically severe respiratory compromise (based on treating physician's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to: a) any underlying pulmonary disorder, b) any autoimmune, connective tissue or inflammatory disorders, c) prior complete pneumonectomy
- Inadequate washout period prior to the first HER3-DXd infusion as specified in protocol
- Clinically significant unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) Grade ≤1 or baseline
- Active hepatitis B virus (HBV) and/or hepatitis C virus infection, such as those with serologic evidence of viral infection within 28 days of the first HER3-DXd infusion
- Human immunodeficiency virus (HIV) infection that is not well controlled
- History of hypersensitivity to either the drug substance or any excipients in HER3-DXd
- Female patient who is pregnant, breast-feeding, or intending to become pregnant
- Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the treating physician's opinion, could affect the safety of the patient.
- Clinically significant corneal disease.
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Program Team Lead, Daiichi Sankyo
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- U31402-0001-EAP-MA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
-
Astellas Pharma Global Development, Inc.WithdrawnSolid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
-
Astellas Pharma Global Development, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) MutationsUnited States
-
Hangzhou Cancer HospitalUnknownNon-small Cell Lung Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)China
-
Black Diamond Therapeutics, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...Korea, Republic of, United States
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsUnited States, Japan, Spain, Italy, Korea, Republic of, Canada, France, Australia, Germany, United Kingdom, Hong Kong, Turkey
-
Guangdong Provincial People's HospitalUnknownNon-small Cell Lung Cancer | Epidermal Growth Factor ReceptorChina
-
Astellas Pharma Global Development, Inc.CompletedNon-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor MutationsUnited States
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
National University Hospital, SingaporeBoehringer IngelheimRecruitingNon-Small Cell Lung Cancer | Epidermal Growth Factor Receptor MutationSingapore
-
Dana-Farber Cancer InstituteAstellas Pharma IncTerminatedNon-Small Cell Lung Cancer | Epidermal Growth Factor ReceptorUnited States
Clinical Trials on HER3-DXd
-
MedSIRDaiichi SankyoRecruitingMetastatic Breast Cancer | Solid Tumor, Adult | Advanced Non-Small Cell Squamous Lung CancerSpain, Austria
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi Sankyo, Inc.RecruitingMetastatic Breast CancerFrance
-
Daiichi SankyoMerck Sharp & Dohme LLCRecruitingMelanoma | Head and Neck Cancer | Gastric Cancer | Advanced Solid TumorJapan
-
Daiichi Sankyo, Inc.Active, not recruitingEGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung CancerKorea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
-
Shanghai Institute Of Biological ProductsShanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruiting
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
Daiichi Sankyo, Inc.RecruitingNon-Small Cell Lung Cancer (NSCLC)United States, Korea, Republic of, Taiwan, Japan
-
Daiichi Sankyo Co., Ltd.RecruitingAdvanced Solid Tumor | Malignant Solid TumorUnited States, Japan
-
Daiichi SankyoMerck Sharp & Dohme LLCNot yet recruitingRecurrent or Metastatic Solid Tumors